Eben’s practice focuses primarily on the defense of pharmaceutical, biotech and other large corporate clients in product liability litigation, government investigations and internal compliance and risk mitigation projects. He has been actively involved in many of the most high-profile cases of the last two decades, including those involving statins, weight loss therapies, anti-inflammatory medications, anticoagulants, anti-anemic agents, oral antidiabetic drugs and acid-reducing therapies. He has extensive practice in MDL and state coordinated proceedings and is regularly engaged as a core member of national counsel teams charged with developing overall litigation strategy and company defense. 

Eben is known for his extensive knowledge of pharmaceutical operations and his ability to navigate the complex legal and regulatory framework governing the marketing and promotion of prescription and OTC pharmaceutical products, including FDA regulations, OIG best practices, the PhRMA Code, and the laws and standards governing labeling requirements, scientific discourse and proper sales practices. He has considerable experience leading large fact investigations, preparing and defending company executives for deposition and at trial, and crafting and implementing expert and trial strategy. He has served on multiple trial teams across a broad array of products, including oral antidiabetic medications, statins, diet drugs and nutraceuticals. 

Eben has received accolades for his defense of major manufacturers of brand name and generic prescription and OTC drug products in several serious injury cases involving the devastating skin reaction known as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Given the high-risk of large trial verdicts resulting from significant personal injury and damages based on long-term care scenarios, such cases present considerable exposure and are heavily litigated on multiple fronts.  Eben has successfully managed all aspects of such cases pending in different federal and state courts across the country. He has been charged with leading the necessary fact investigations, defending the core company witnesses in depositions on various subjects, developing expert strategy and the litigation endgame, and ultimately playing a key role in obtaining favorable results in these matters.

Eben was a core member of the trial team for the first two trials involving an oral antidiabetic medication in the Philadelphia Court of Common Pleas, where he was charged with arguing the critical evidentiary issues arising out of claims of spoliation. He was also responsible for developing the core case-specific evidence in several cases involving an anticoagulant therapy, including the second national bellwether case that was tried to a defense verdict.